LIPI- PROTECT-2 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP2) (LPP2)
Effect of the Dietary Supplement LIPI-PROTECT-2 on Plasma LDL Cholesterol Concentration in Subjects With Moderate Hypercholesterolemia: A Pilot Study.
This is a multicenter, uncontrolled pilot study evaluating changes in plasma LDL-cholesterol (LDL-C) concentrations before and after 3 months of intake of the dietary supplement LIPI-PROTECT-2.The main objective of this clinical trial is to evaluate the effect of LIPI-PROTECT-2 on plasma LDL-C concentration after 3 months of supplementation in participants with untreated moderate hypercholesterolemia.A mean reduction in plasma LDL-C levels of approximately 14% (0.20 g/L) is expected after 3 months of supplementation.The primary endpoint is the absolute (g/L) and relative (%) change in plasma LDL-C concentration between baseline and Month 3.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for coronary cardiovascular disease. In individuals at low cardiovascular risk, lifestyle and dietary measures are recommended to reduce LDL-C levels and/or overall cardiovascular risk. Dietary supplements may be considered as part of these measures when their efficacy has been demonstrated.LIPI-PROTECT-2 is a dietary supplement containing plant extracts and vitamins that may contribute to reducing plasma LDL-C levels. Some of its individual active ingredients have previously been investigated in clinical studies and have shown an LDL-C-lowering effect. However, the combination of these active ingredients has not previously been evaluated in a clinical study.This pilot, multicenter, uncontrolled study is designed to provide preliminary estimates of the effect of LIPI-PROTECT-2 in adults with untreated moderate hypercholesterolemia.A total of 20 men and women aged 18 to 65 years with untreated moderate hypercholesterolemia will be included. Participants will have an LDL-C level ≥1.5 g/L and a low cardiovascular risk. They will consume LIPI-PROTECT-2 for 3 months and will be required to maintain stable body weight, dietary habits, and physical activity throughout the study.The primary objective is to assess the effect of LIPI-PROTECT-2 on plasma LDL-C concentration after 3 months of supplementation. The primary outcome will be the absolute and relative change in LDL-C concentration between baseline and Month 3. A mean reduction of approximately 14% (0.20 g/L) in LDL-C is expected after 3 months of supplementation.Secondary objectives are to evaluate the effect of LIPI-PROTECT-2 after 1 and 3 months compared with baseline on body weight, body mass index, waist circumference, systolic and diastolic blood pressure, resting heart rate, fasting glucose, LDL-C, non-HDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, LDL-C/HDL-C and total cholesterol/HDL-C ratios, and the atherogenic index (non-HDL-C/HDL-C).Safety will also be assessed by comparing selected laboratory parameters between baseline and Month 3, including AST, ALT, gamma-glutamyl transferase, creatine kinase, lactate dehydrogenase, bilirubin, creatinine, and urea. Adherence to the dietary supplement will be assessed throughout the study.Participants with high or very high cardiovascular risk, lipid-lowering treatment, diabetes, severe chronic diseases, or concomitant treatments likely to interfere with the assessment of efficacy or safety will be excluded.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Coralie BERTHIER, PhD
- Telefonnummer: +33 0320877333
- E-Mail: coralie.berthier@pasteur-lille.fr
Studieren Sie die Kontaktsicherung
- Name: Frédéric BATTEUX, MD
- Telefonnummer: +33 320877316
- E-Mail: frederic.batteux@pasteur-lille.fr
Studienorte
-
-
Nord
-
Lille, Nord, Frankreich, 59019
- Rekrutierung
- Prevention research center - Institut Pasteur of Lille
-
Kontakt:
- Coralie BERTHIER, PhD
- Telefonnummer: +33 0320877333
- E-Mail: coralie.berthier@pasteur-lille.fr
-
Kontakt:
- Bérengère LEGENDRE
- Telefonnummer: +33 0320877346
- E-Mail: berengere.legendre@pasteur-lille.fr
-
Hauptermittler:
- Frédéric BATTEUX, MD
-
-
Vaucluse
-
Avignon, Vaucluse, Frankreich, 84140
- Rekrutierung
- Biophysium Avignon
-
Kontakt:
- Gaetan BOLEA, PhD
- Telefonnummer: +33 0660663995
- E-Mail: g.bolea@biophysium.com
-
Kontakt:
- Romain CAYUELA, MD
- Telefonnummer: +33 0629355794
- E-Mail: docteur.cayuelaromain@gmail.com
-
Hauptermittler:
- Romain CAYUELA, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Men and women aged 18-65 years For women :If pre-menopausal: effective non-estrogenic* contraception initiated at least 2 cycles prior and maintained throughout the studyIf post-menopausal: not receiving estrogenic* Hormone Replacement Therapy (HRT)
- LDL-cholesterol ≥ 1.5 g/L (calculated using the Friedewald formula)
- Aware of their hypercholesterolemia and previously informed about the associated lifestyle and dietary measures
- BMI between 20 and 35 kg/m² (inclusive)
- Stable weight, dietary habits, and physical activity level for at least 3 months prior to the start of the study, with agreement to maintain them throughout the study
- Willing to comply with study requirements
- Signed informed consent
Exclusion Criteria:
- Subjects receiving lipid-lowering or anti-dyslipidemic therapy (statins, ezetimibe, cholestyramine, fibrates, etc.)
- Subjects with triglyceride levels > 4 g/L
- Subjects requiring immediate lipid-lowering therapy
- Subjects with diabetes (whether treated with medication or not, or diagnosed during the initial visit based on fasting blood glucose > 1.26 g/L)
- Subjects receiving beta-blockers and/or diuretics
- Subjects at high or very high cardiovascular risk according to ESC/EAS 2025 guidelines (assessed using the SCORE2 score, Appendix 2)
- Subjects receiving anticoagulant therapy
- Subjects receiving antiretroviral therapy
- Subjects requiring immediate dietary intervention, or exhibiting fluctuating eating habits or an eating disorder (anorexia, bulimia, binge eating disorder)
- Subjects on unstable treatment (initiated less than three months prior) or requiring the initiation of treatment during the study that, in the investigator's opinion, could interfere with the assessment of study endpoints (efficacy parameters: LDL, TG, HDL, blood glucose, blood pressure, weight; safety parameters: markers of hepatic, muscular, or renal function)
- Subjects who have consumed dietary supplements or functional foods capable of affecting cholesterol or triglyceride levels (phytosterols, phytostanols, red yeast rice, policosanols, beta-glucans at doses exceeding 3 g/day, artichoke or garlic extracts, probiotics, etc.) within the last 6 weeks
- Subjects suffering from a severe chronic condition deemed incompatible with participation in the study by the investigator (serious digestive disorders, renal insufficiency, coronary artery disease, immunodeficiency, heart failure, rhythm disorders, active malignancy, hematological disease)
- Subjects with an allergy to any of the components of LIPI-PROTECT-2 Pregnant or breastfeeding women, or women intending to become pregnant within the next 4 months Subjects under legal protection (guardianship/curatorship, deprivation of liberty) or not covered by a social security scheme
- Subjects participating in another clinical study or currently within the exclusion period of another study
- Subjects whose condition is judged by the principal investigator or a qualified co-investigator deems that their health status or concomitant treatments are incompatible with the proper conduct of the clinical study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Food supplement group
Three tablets of LIPI-PROTECT-2 per day (1 at the end or after breakfast and 2 during dinner). Food supplements are consumed during 3 months by healthy volunteers |
All subjects will consume 4 capsules per day during the entire intervention period, i.e. 12 weeks between V0 and V3, distributed as follows: 2 capsules in the morning at the end of or after breakfast (no taking on an empty stomach) and 2 capsules in the evening during dinner. If a dose is missed, 1 capsule can be taken at the next dose |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
To evaluate the effect of LIPI-PROTECT-2 on plasma LDL-cholesterol concentration (absolute value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia
Zeitfenster: To baseline at 3 months
|
To evaluate the absolute (g/L) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3). |
To baseline at 3 months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
To evaluate the effect of LIPI-PROTECT-2 on plasma LDL-cholesterol concentration (relative value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia.
Zeitfenster: To baseline at 3 months
|
To evaluate the relative (%) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3). |
To baseline at 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on LDL cholesterol.
Zeitfenster: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in LDL cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on Non HDL cholesterol.
Zeitfenster: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in Non HDL cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on total cholesterol.
Zeitfenster: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in total cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on HDL cholesterol.
Zeitfenster: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in HDL cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on triglycerides.
Zeitfenster: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on triglycerides in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on non HDL cholesterol/LDL (atherogenic index).
Zeitfenster: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non HDL cholesterol/LDL (atherogenic index) (ratio). |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on ratio LDL/HDL.
Zeitfenster: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non ratio LDL/HDL (ratio). |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on ratio total cholesterol/HDL.
Zeitfenster: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on ratio total cholesterol/HDL (ratio). |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on fasting blood glucose levels.
Zeitfenster: At baseline, 1 month and 3 months
|
Variation in fasting blood glucose (unit: g/l) between VS, V1, and V3 |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on weight.
Zeitfenster: At baseline, 1 month and 3 months
|
Changes in weight (unit : kilograms) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on Body Mass Index (BMI).
Zeitfenster: At baseline, 1 month and 3 months
|
Changes in BMI (weight and height will be combined to report BMI) in kg/m^2between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on waist circumference.
Zeitfenster: At baseline, 1 month and 3 months
|
Changes in waist circumference (unit: cm) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on arterial blood pressure
Zeitfenster: At baseline, 1 month and 3 months
|
Variation in systolic blood pressure and diastolic blood pressure (unit: mm Hg) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on heart rate
Zeitfenster: At baseline, 1 month and 3 months
|
Variation in Heart rate (unit: Pul/min) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on hepatic metabolism: ASAT/ALAT, GGT
Zeitfenster: At baseline and 3 months
|
Changes in safety biomarkers : ASAT/ALAT and GGT(unit: UI/l) between baseline and V3 . |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on hepatic metabolism : Creatinine, bilirubin
Zeitfenster: At baseline and 3 months
|
Changes in safety biomarkers : Creatinine, bilirubin (unit: mg/dl) between baseline and V3. |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on renal metabolism : Urea
Zeitfenster: At baseline and 3 months
|
Changes in safety biomarkers : Urea (unit: mg/dl) between baseline and V3. |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on renal metabolism : Creatinine Phophoskinase (CPK)
Zeitfenster: At baseline and 3 months
|
Changes in safety biomarkers : CPK (unit : UI/l) between baseline and V3. |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on Renal metabolism : Lactate Deshydrogenase (LDH)
Zeitfenster: At baseline and 3 months
|
Changes in safety biomarkers : LDH (unit : UI/l) between baseline and V3. |
At baseline and 3 months
|
|
To assess adherence to LIPI-PROTECT-2 consumption by pillbox weighing
Zeitfenster: At baseline, 1 month and 3 months
|
Adherence assessed by weighing the pillbox at each visit and comparing the weight with the initial weight recorded at baseline (V0). |
At baseline, 1 month and 3 months
|
|
To assess self-reported adherence to LIPI-PROTECT-2 consumption
Zeitfenster: At baseline, 1 month, 2 months and 3 months
|
Adherence assessed through participant self-reporting of supplement consumption and missed doses. |
At baseline, 1 month, 2 months and 3 months
|
|
To assess adherence to LIPI-PROTECT-2 consumption by counting returned tablets
Zeitfenster: At 3 months
|
Adherence assessed by counting the remaining tablets returned by participants at the end of the study. |
At 3 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienstuhl: Coralie BERTHIER, PhD, Institut Pasteur of Lille
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Stoffwechsel, angeborene Fehler
- Genetische Krankheiten, angeboren
- Stoffwechselerkrankungen
- Hyperlipidämien
- Dyslipidämien
- Störungen des Fettstoffwechsels
- Fettstoffwechsel, angeborene Fehler
- Hyperlipoproteinämien
- Angeborene, erbliche und neonatale Krankheiten und Anomalien
- Ernährungs- und Stoffwechselerkrankungen
- Hypercholesterinämie
- Hyperlipoproteinämie Typ II
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2026-A00950-51
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .